Patents by Inventor Adivaraha Jayasankar

Adivaraha Jayasankar has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Solid Pharmaceutical Compositions for Treating HCV
    Publication number: 20240075026
    Abstract: The present invention features solid pharmaceutical compositions comprising Compound 1 and Compound 2. In one embodiment, the solid pharmaceutical composition includes (1) a first layer which comprises 100 mg Compound 1, as well as a pharmaceutically acceptable hydrophilic polymer and a pharmaceutically acceptable surfactant, all of which are formulated in amorphous solid dispersion; and (2) a second layer which comprises 40 mg Compound 2, as well as a pharmaceutically acceptable hydrophilic polymer and a pharmaceutically acceptable surfactant, all of which are formulated in amorphous solid dispersion.
    Type: Application
    Filed: February 8, 2023
    Publication date: March 7, 2024
    Applicant: AbbVie Inc.
    Inventors: Nancy E. Sever, Ulrich Westedt, Ute Lander, Katrin Schneider, Benedikt Steitz, Thomas Mueller, Regina Reul, Constanze Obermiller, Adivaraha Jayasankar, Michael Simon, Yi Gao, Harald Hach, Samuel Kyeremateng, Katharina Asmus, Ping Tong, Donghua Zhu, Marius Naris, Colleen Garrett
  • Solid pharmaceutical compositions for treating HCV
    Patent number: 11246866
    Abstract: The present invention features solid pharmaceutical compositions comprising Compound 1 and Compound 2. In one embodiment, the solid pharmaceutical composition includes (1) a first layer which comprises 100 mg Compound 1, as well as a pharmaceutically acceptable hydrophilic polymer and a pharmaceutically acceptable surfactant, all of which are formulated in amorphous solid dispersion; and (2) a second layer which comprises 40 mg Compound 2, as well as a pharmaceutically acceptable hydrophilic polymer and a pharmaceutically acceptable surfactant, all of which are formulated in amorphous solid dispersion.
    Type: Grant
    Filed: October 16, 2019
    Date of Patent: February 15, 2022
    Assignee: AbbVie Inc.
    Inventors: Nancy E. Sever, Ulrich Westedt, Ute Lander, Katrin Schneider, Benedikt Steitz, Thomas Mueller, Regina Reul, Constanze Obermiller, Adivaraha Jayasankar, Michael Simon, Yi Gao, Harald Hach, Samuel Kyeremateng, Katharina Asmus, Ping Tong, Donghua Zhu, Marius Naris, Colleen Garrett
  • Solid Pharmaceutical Compositions for Treating HCV
    Publication number: 20200282004
    Abstract: The present invention features solid pharmaceutical compositions comprising Compound 1 and Compound 2. In one embodiment, the solid pharmaceutical composition includes (1) a first layer which comprises 100 mg Compound 1, as well as a pharmaceutically acceptable hydrophilic polymer and a pharmaceutically acceptable surfactant, all of which are formulated in amorphous solid dispersion; and (2) a second layer which comprises 40 mg Compound 2, as well as a pharmaceutically acceptable hydrophilic polymer and a pharmaceutically acceptable surfactant, all of which are formulated in amorphous solid dispersion.
    Type: Application
    Filed: October 16, 2019
    Publication date: September 10, 2020
    Applicant: AbbVie Inc.
    Inventors: Nancy E. Sever, Ulrich Westedt, Ute Lander, Katrin Schneider, Benedikt Steitz, Thomas Mueller, Regina Reul, Constanze Obermiller, Adivaraha Jayasankar, Michael Simon, Yi Gao, Harald Hach, Samuel Kyeremateng, Katharina Asmus, Ping Tong, Donghua Zhu, Marius Naris, Colleen Garrett
  • Solid Pharmaceutical Compositions for Treating HCV
    Publication number: 20200253968
    Abstract: The present invention features solid pharmaceutical compositions comprising Compound 1 and Compound 2. In one embodiment, the solid pharmaceutical composition includes (1) a first layer which comprises 100 mg Compound 1, as well as a pharmaceutically acceptable hydrophilic polymer and a pharmaceutically acceptable surfactant, all of which are formulated in amorphous solid dispersion; and (2) a second layer which comprises 40 mg Compound 2, as well as a pharmaceutically acceptable hydrophilic polymer and a pharmaceutically acceptable surfactant, all of which are formulated in amorphous solid dispersion.
    Type: Application
    Filed: October 16, 2019
    Publication date: August 13, 2020
    Applicant: AbbVie Inc.
    Inventors: Nancy E. Sever, Ulrich Westedt, Ute Lander, Katrin Schneider, Benedikt Steitz, Thomas Mueller, Regina Reul, Constanze Obermiller, Adivaraha Jayasankar, Michael Simon, Yi Gao, Harald Hach, Samuel Kyeremateng, Katharina Asmus, Ping Tong, Donghua Zhu, Marius Naris, Colleen Garrett
  • Solid Pharmaceutical Compositions for Treating HCV
    Publication number: 20190216882
    Abstract: The present invention features solid pharmaceutical compositions comprising Compound 1 and Compound 2. In one embodiment, the solid pharmaceutical composition includes (1) a first layer which comprises 100 mg Compound 1, as well as a pharmaceutically acceptable hydrophilic polymer and a pharmaceutically acceptable surfactant, all of which are formulated in amorphous solid dispersion; and (2) a second layer which comprises 40 mg Compound 2, as well as a pharmaceutically acceptable hydrophilic polymer and a pharmaceutically acceptable surfactant, all of which are formulated in amorphous solid dispersion.
    Type: Application
    Filed: December 20, 2018
    Publication date: July 18, 2019
    Applicant: AbbVie Inc.
    Inventors: Nancy E. Sever, Ulrich Westedt, Ute Lander, Katrin Schneider, Benedikt Steitz, Thomas Mueller, Regina Reul, Constanze Obermiller, Adivaraha Jayasankar, Michael Simon, Yi Gao, Harald Hach, Samuel Kyeremateng, Katharina Asmus, Ping Tong, Donghua Zhu, Marius Naris, Colleen Garrett
  • Solid Pharmaceutical Compositions for Treating HCV
    Publication number: 20160375017
    Abstract: The present invention features solid pharmaceutical compositions comprising Compound 1 and Compound 2. In one embodiment, the solid pharmaceutical composition includes (1) a first layer which comprises 100 mg Compound 1, as well as a pharmaceutically acceptable hydrophilic polymer and a pharmaceutically acceptable surfactant, all of which are formulated in amorphous solid dispersion; and (2) a second layer which comprises 40 mg Compound 2, as well as a pharmaceutically acceptable hydrophilic polymer and a pharmaceutically acceptable surfactant, all of which are formulated in amorphous solid dispersion.
    Type: Application
    Filed: July 18, 2016
    Publication date: December 29, 2016
    Applicant: AbbVie Inc.
    Inventors: Katharina Asmus, Yi Gao, Colleen Garrett, Harald Hach, Adivaraha Jayasankar, Kyeremateng Samuel, Ute Lander, Thomas Mueller, Marius Naris, Constanze Obermiller, Regina Reul, Katrin Schneider, Nancy Sever, Michael Simon, Benedikt Steitz, Ping Tong, Ulrich Westedt, Donghua Zhu
  • Solid Pharmaceutical Compositions for Treating HCV
    Publication number: 20160375087
    Abstract: The present invention features solid pharmaceutical compositions comprising Compound 1 and Compound 2. In one embodiment, the solid pharmaceutical composition includes (1) a first layer which comprises 100 mg Compound 1, as well as a pharmaceutically acceptable hydrophilic polymer and a pharmaceutically acceptable surfactant, all of which are formulated in amorphous solid dispersion; and (2) a second layer which comprises 40 mg Compound 2, as well as a pharmaceutically acceptable hydrophilic polymer and a pharmaceutically acceptable surfactant, all of which are formulated in amorphous solid dispersion.
    Type: Application
    Filed: June 24, 2016
    Publication date: December 29, 2016
    Applicant: AbbVie Inc.
    Inventors: Nancy E. Sever, Ulrich Westedt, Ute Lander, Katrin Schneider, Benedikt Steitz, Thomas Mueller, Regina Reul, Constanze Obermiller, Adivaraha Jayasankar, Michael Simon, Yi Gao, Harald Hach, Samuel Kyeremateng, Katharina Asmus, Ping Tong, Donghua Zhu, Marius Naris, Colleen Garrett
  • FORMULATIONS OF PHENYL URACIL COMPOUNDS
    Publication number: 20160106849
    Abstract: A pharmaceutical product comprising at least one phenyl uracil-based pharmaceutically active agent or an agent of related structural type and processes for obtaining such product.
    Type: Application
    Filed: December 22, 2015
    Publication date: April 21, 2016
    Inventors: Huailiang Wu, Hao Hou, Adivaraha Jayasankar, Ameesha Patel, David Beno, Eric A. Schmitt, Geoff G. Zhang
  • Formulations of phenyl uracil compounds
    Patent number: 9248193
    Abstract: A pharmaceutical product comprising at least one phenyl uracil-based pharmaceutically active agent or an agent of related structural type and processes for obtaining such product.
    Type: Grant
    Filed: March 16, 2012
    Date of Patent: February 2, 2016
    Assignee: AbbVie Inc.
    Inventors: Huailiang Wu, Hao Hou, Adivaraha Jayasankar, Ameesha Patel, David Beno, Eric A. Schmitt, Geoff G. Zhang
  • Formulations of Phenyl Uracil Compounds
    Publication number: 20140378490
    Abstract: A pharmaceutical product comprising at least one phenyl uracil-based pharmaceutically active agent or an agent of related structural type and processes for obtaining such product.
    Type: Application
    Filed: March 16, 2012
    Publication date: December 25, 2014
    Applicant: AbbVie Inc.
    Inventors: Huailiang Wu, Hao Hou, Adivaraha Jayasankar, Ameesha Patel, David Beno, Eric A. Schmitt, Geoff G. Zhang